ViCardia Therapeutics, Inc.
ViCardia Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for heart failure involving mitochondrial dysfunction, with a mission to lead in research and treatment targeting mitochondrial dysfunction and AMPK activation to improve patient lifespan and healthspan.
Industries
Nr. of Employees
small (1-50)
ViCardia Therapeutics, Inc.
930 Montgomery Street, Suite 600, San Francisco, CA 94133
Products
Clinical‑stage infusion therapy (AMPK-activating small molecule)
A clinical-stage intravenous therapy designed to activate AMPK, restore mitochondrial energetics, enhance oxidative phosphorylation, increase endogenous adenosine during cellular stress, and improve cardiac contractile function in acute decompensated and chronic heart failure.
Clinical‑stage infusion therapy (AMPK-activating small molecule)
A clinical-stage intravenous therapy designed to activate AMPK, restore mitochondrial energetics, enhance oxidative phosphorylation, increase endogenous adenosine during cellular stress, and improve cardiac contractile function in acute decompensated and chronic heart failure.
Services
Business development and partnering to advance clinical-stage therapeutics toward regulatory approval and market access.
Business development and partnering to advance clinical-stage therapeutics toward regulatory approval and market access.
Expertise Areas
- Clinical trial management
- Cardiovascular drug development
- Mitochondrial-targeted therapeutics
- Translational pharmacology
Key Technologies
- AMP-activated protein kinase (AMPK) activation
- Oxidative phosphorylation modulation
- Endogenous adenosine modulation
- Intravenous infusion therapeutics